Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:18 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
NCT06420297 · ACADIA Pharmaceuticals Inc. · PHASE3 · terminated · last registry update 2026-08-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Primary efficacy endpoint was not met in the parent study (ACP-101-302). Based on review of available data, continued administration of investigational product in ACP-101-303 was not considered likely to provide significant clinical benefit.” | – | Registry record, ACADIA Pharmaceuticals Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against OXTR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-06Also stopped (withdrawn): Florida State University, a drug against OXTR (NCT06710964)
- 2026-11-06Also stopped (withdrawn): Florida State University, a drug against OXTR (NCT06713473)
- 2026-11-03Results posted on the registry: University of California, Los Angeles, Oxytocin nasal spray + Placebo nasal spray (NCT03245437)
- 2026-10-26Also stopped (withdrawn): University of Roma La Sapienza, a drug against OXTR (NCT07010653)
- 2026-10-15Also stopped (terminated): University Hospital, Clermont-Ferrand, Oxytocin + Misoprostol Oral Tablet (NCT05568745)
- 2026-10-15Results posted on the registry: ACADIA Pharmaceuticals Inc., Carbetocin + Placebo (NCT06173531)
- 2026-10-13Also stopped (terminated): Wake Forest University Health Sciences, Oxytocin + Placebo (NCT04427709)
- 2026-09-04Also stopped (terminated): Aalto University, a drug against OXTR (NCT07214948)
- 2026-07-02Also stopped (suspended): Icahn School of Medicine at Mount Sinai, 40 IU Intranasal Oxytocin + Placebo (NCT02225600)
- 2026-06-11Results posted on the registry: University of Washington, Oxytocin nasal spray or placebo (NCT05968651)
- 2026-03-27Also stopped (terminated): Assistance Publique - Hôpitaux de Paris, Misoprostol (NCT01113229)
- 2026-03-11Results posted on the registry: VA Office of Research and Development, Oxytocin (NCT04228289)
- 2026-02-23Results posted on the registry: University of Florida, Oxytocin (OT) + Placebo (P) (NCT03878589)
- 2026-01-26Also stopped (terminated): Baylor Research Institute, Pitocin (NCT02910115)
- 2026-01-20Results posted on the registry: VA Office of Research and Development, Oxytocin + Placebo (NCT03900754)
- 2026-01-20Also stopped (terminated): VA Office of Research and Development, Oxytocin + Placebo (NCT03900754)
- 2026-01-09Results posted on the registry: The University of Texas Medical Branch, Galveston, Oxytocin (Low dose) + Oxytocin (High dose) (NCT05782816)
- 2025-10-28Results posted on the registry: Wake Forest University Health Sciences, Oxytocin (NCT05929339)
- 2025-10-16Results posted on the registry: Brigham and Women's Hospital, 15-methyl prostaglandin F2α + Methylergonovine Maleate (NCT03584854)
- 2025-09-11Also stopped (terminated): Wake Forest University Health Sciences, Oxytocin (NCT04431206)
- 2025-08-29Results posted on the registry: Wake Forest University Health Sciences, Oxytocin (NCT04431206)
- 2025-08-28Results posted on the registry: Baylor College of Medicine, Oxytocin (NCT05405257)
- 2025-08-28Also stopped (terminated): Baylor College of Medicine, Oxytocin (NCT05405257)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision